New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials

Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Martin J. van den Bent(Erasmus MC Cancer Institute), Evanthia Galanis(Mayo Clinic in Arizona), Jan C. Buckner(McGill University), Minesh P. Mehta(Columbia University), Roger Stupp(Northwestern University), Paul D. Brown(Mayo Clinic), Brigitta G. Baumert(Kantonsspital Graubünden), Edward Shaw(Wake Forest University), M. Wang(North Central Cancer Treatment Group), Denis Lacombe(European Organisation for Research and Treatment of Cancer), Wenting Wu(East China Normal University)
Neuro-Oncology
September 18, 2013
10.1093/neuonc/not117
Cited by 132

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k